ASHA American Social Health Association


Sitemap | Contact Us | Home
Learn about STDsAbout ASHANewsPublicationsGet Involved
  
Overview
Chancroid
Chlamydia
Crabs
Gonorrhea
Hepatitis
Hepatitis for Men
Herpes
HIV and AIDS
HPV
Molluscum Contagiosum
NGU
PID
Scabies
Syphilis
Vaginitis/Trichomoniasis
Using a Condom
STD/STI Statistics
STD/STI Prevention Tips
Sexual Health Glossary
Herpes Resource CenterHPV Resource CenterHPV Resource CenterGet testing information here

FEATURED NEWS
FDA Rules onCervical Cancer Vaccines
Hispanic Communities in the U.S. Impacted by HIV/AIDS Experimental HIV Vaccine Prevents Infection in Nearly 1/3 of Subjects Merck and Qiagen Announce Partnership
CDC Report: Youth at Risk for STDs, Unwanted Pregnancy

 

Have a question about sexual health or STIs? Then check out ASHA's newsest feature--Ask the Experts. Professionals in the field of sexual and reproductive health answer your questions.

Featured publication

HPV and Men

*NEW!* Our latest brochure, HPV: A Guide for Men is designed specifically with the male patient in mind. Addressing such issues as the lack of testing options for men and potential concerns about penile and anal cancer, the brochure touches upon important issues for men and their partners. Click here to order today.




Need information about?...
• Donating to ASHA
• STI Hotline
• Herpes Newsletter
• HPV Newsletter
• Teen Sexual Health
• Talking to Your Kids
• ASHA's eNewsletter
• Links to Related Sites
• Advertising on this site
• State STD Prevention
• STI Message Board





All rights reserved | Site Use and Privacy Statements
An HIV vaccine being tested in Thailand
prevented infection in 31% of subjects,
prompting experts to laud the results
while cautioning that much work remains.
According to the CDC, /Latino men
are diagnosed with AIDS at a rate
three times that of whites. Among
women, the figures are even more
sobering, as the rate of AIDS in Latinas
exceeds that of white women by five-fold.
On October 16, the U.S. Food and Drug
Administration announced two major
rulings with HPV/cervical cancer vaccines,
approving GlaxoSmithKline’s cervical cancer
vaccine, Cervarix®, for use in the U.S. with
females ages 10-25 and green-lighting use
of Merck’s Gardasil® with boys.
Merck and QIAGEN will collaborate
to combat cervical cancer in the
developing world, the companies
announced in September at the
annual meeting of the Clinton Global
Initiative in New York.
Young people commonly engage in risky
sexual behaviors (sex at a young age and/or
unprotected sex) and increasingly are at
risk for STDs and pregnancy, according to
a report published by the Centers for Disease
Control and Prevention (CDC).